Publications

Analysis of Oritavancin In Vitro Activity against Enterococcal Isolates from US Medical Centers and Resistant Subsets. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal
#116

Activity of Meropenem-Vaborbactam and Comparator Agents against Multidrug-Resistant Enterobacteriaceae Isolates from the United States Analyzed by Site of Infection. Lead author: M Castanheira, presented at ESMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#117

Spectrum of Activity of RX-P2382, a Novel Class of Bacterial Ribosome Inhibitor. Lead author: D Shortridge, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#46

Tedizolid In Vitro Activity against a Contemporary Challenge Collection of Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: CG Carvalhaes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#111

In Vitro Activity Evaluation of a Next-Generation Polymyxin, SPR206, against Non-Fermentative Gram-Negative Bacilli Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#80

Activity of an Investigational Polymyxin-B-Like Compound (SPR206) against a Set of Enterobacteriaceae Organisms Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#81

The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States. Lead author: H Sader, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#107

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. by Sader HS, Flamm RK, Dale GE, Rhomberg PR and Castanheira M published in J Antimicrob Chemother. 2018; 73: 2400-2404

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS. published in J. Antimicrob. Chemother. 2018; 73 (10) 2748-2756

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). by Sader HS, Castanheira M, Mendes RE and Flamm RK published in J. Antimicrob. Chemother.: in press, 2018.

Delafloxacin in vitro broth microdilution and disk diffusion antimicrobial susceptibility testing guidelines: Susceptibility breakpoint criteria and quality control ranges for an expanded spectrum anionic fluoroquinolone. by Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D and Jones RN published in J. Clin. Microbiol. 2018; 56 (8): e00339

Disruption of mgrB and Alterations on pmrB Are Most Common Resistance Mechanisms among Colistin-Resistance among Klebsiella pneumoniae from a Global Surveillance Program. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-467

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-393

Global Trends in Prevalence and Diversity of Carbapenemases Carrying Enterobacteriaceae Identified through SENTRY Antimicrobial Surveillance Program. Lead author: LM Deshpande, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-404https://www.jmilabs.com/wp-admin/post.php?post=6561&action=edit#

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Multidrug-Resistant Streptococcus pneumoniae (2014-2017): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-397

Antimicrobial Activity of the Novel Siderophore Cehpalosporin GT-1 Tested Alone and Combined with the β-Lactamase Inhibitor GT-055 against Molecularly Characterized Enterobacteriaceae Clinical Isolates. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-571

Antimicrobial Activity Assessment of Tebipenem (SPR859) against an Isolate Collection Causing Urinary Tract Infections. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-560

Antimicrobial Activity of Ceftobiprole When Tested against Gram-Positive Cocci Causing Serious Infections (2016-2017): Endocarditis, Diabetic Foot, and Bone/Joint Infections. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-581

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by United States Census Divisions: Results from the 2017 INFORM Program. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA.
# Sunday-388

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Isolates Collected from Hematology or Oncology Patients in Europe during 2011-2017 as Part of a Global Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-394

Antimicrobial Activity of Tebipenem (SPR859) against a Global Challenge Set of Enterobacteriaceae Isolates. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-558

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Intensive Care Unit Patients with Pneumonia in US Medical Centers. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-392

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Lead author: DJ Diekema, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-400

Characterization of Variant mcr-1.11 and Prevalence of mcr Genes among Escherichia coli and Klebsiella pneumonia Clinical Isolates Collected Worldwide. Lead author: LM Deshpande, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-468

Antimicrobial Activity of GT-1, a Novel Siderophore Cephalosprin, Tested against Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter spp. Isolates. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-577

Fosfomycin Activity against Gram-Negative Isolates from Eastern Europe Collected by the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-632

Omadacycline In Vitro Activity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the United States and Europe During the 2017 SENTRY Surveillance Program. Lead author: MD Huband. Presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-627

Activity of Fosfomycin against Gram-Negative Baseline Bacterial Isolates from Patients in a Phase 3 Complicated Urinary Tract Infection Trial (ZEUS). Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-633

Molecular Characterization of Clinical Trial Isolates Exhibiting Increased MIC Results during Fosfomycin (ZTI-01) Treatment in a Phase 2/3 Clinical Trial for Complicated Urinary Tract Infections (ZEUS). Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-637

Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-645

Distribution of β-Lactamase Resistance Genes and Lineage Background in Clinical Isolates Producing Extended-Spectrum β-Lactamases by High-Resolution Genomic Analysis. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-426

Correlation between Broth Microdilution and Disk Diffusion Methods Results When Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Molecular Characterization of Isolates with Elevated Ceftaroline MIC Results. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-214

Molecular Characterization of Resistance Mechanisms Associated with Pleuromutilins Among Gram-Positive Clinical Isolates From the Worldwide SENTRY Surveillance Studies for Lefamulin. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-642

Current Assessment of Oritavancin Activity against Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-452

In Vitro Activity of Tedizolid and Comparator Agents Tested against Gram-Positive Isolates Causing Serious Infections in Hospitalized Patients in the United States and Europe. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-453

In Vitro Activity of a Novel Extended-Spectrum β-Lactamase Inhibitor, AAI101, in Combination with Cefepime, against Enterobacteriaceae Isolates Collected during 2016. Lead author: MD Huband, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-601

Activity of Telavancin against a Contemporary Collection of Staphylococcus aureus Clinical Isolates from All 9 US Census Bureau Divisions. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-416

Twenty-Year Trends in Antibiotic Susceptibility among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program. Lead author: DJ Diekema, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-425

Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Asia, and Latin America: Results from 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016). Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-447

Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-2016. Lead author: MA Pfaller, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-450

Activity of a Long-Acting Echinocandin Rezafungin (CD101) and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2016. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-485

Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Castanheira M, Flamm RK and Mendes RE published in J Antimicrob Chemother. 2018: 73 (9); 2314-2322

In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from United States hospitals and comparative activity of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. by Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (8): e00313

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the program to assess ceftolozane-tazobactam susceptibility (PACTS) surveillance program. by Shortridge D, Pfaller MA, Castanheira M and Flamm RK published in Diagn. Microbiol. Infect. Dis.: in press, 2018.

Ceftazidime-avibactam antimicrobial activity and spectrum when tested against Gram-negative organisms from pediatric patients: Results from the INFORM Surveillance Program (United States, 2011-2015). by Sader HS, Huband MD, Duncan LR and Flamm RK published in Pediatr. Infect. Dis. 2018; J. 37 (6): 549-554

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16). by Pfaller MA, Sader HS, Castanheira M, Flamm RK and Mendes RE published in J. Antimicrob. Chemother. 2018; 73 (4): 916-922

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. by Pfaller MA, Sader HS, Flamm RK, Castanheira M and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2018; 91 (2): 199-204

Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. by Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK published in Int. J. Antimicrob. Agents. 2018; 52 (2) 287-292

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa from the United States, Europe, and China. by Sader HS, Dale GE, Rhomberg PR and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (7): e00311

Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds. by Pfaller MA, Rhomberg PR and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2018: 92 (1); 43-45